Data Dose August 2024 #4
Drug-Induced Nightmares: When Dreams Turn Dark
Nightmares are a common experience that disrupts sleep, but when triggered by medication, they can indicate more serious underlying concerns. For the pharmacovigilance community, recognizing and addressing drug-induced nightmares is essential for safeguarding patient safety and well-being. This discussion explores the issue by examining a case study in the medical literature, highlighted through the DrugCard platform. Read more...
A study linking popular weight loss drug to suicide risk again raises long-standing safety questions
A new study from an international drug safety database suggests that people taking semaglutide, a popular medication for diabetes and weight loss, may be more likely to report suicidal thoughts compared to those on other drugs. However, the evidence on the link between semaglutide and mood issues, including depression and suicide, remains inconclusive, with critics arguing that the connection is limited. Semaglutide is marketed as Ozempic for diabetes and Wegovy for weight loss, with compounded versions also available. Despite these concerns, the drug's use has surged, with studies highlighting its benefits, such as reducing kidney disease and cancer risks. Read more...
领英推荐
Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database
The study analyzed 2,216 reports on EV-related adverse events (AEs), revealing strong signals for severe cutaneous reactions, retroperitoneal fibrosis, and peripheral neuropathy. Of 116 significant disproportionality signals, 49 were not listed on the EV drug label. Commonly reported AEs included rash, peripheral neuropathy, and alopecia, with most occurring within 30 days of treatment. The analysis suggests that dermatologic toxicity and peripheral neuropathy are key concerns, with additional unlisted AEs mainly involving gastrointestinal, hepatic, and pulmonary issues. Further research is needed to confirm these findings. Read more...
New Technique May Reveal Repurposing Potential for Existing Drugs
A new technique called decryptE, developed by researchers at the Technical University of Munich (TUM), may uncover unknown benefits of existing drugs. This approach could lead to new applications for approved drugs and advance precision medicine. In the decryptE method, lab-grown cells are exposed to varying drug doses over 18 hours, and mass spectrometry analyzes the effects on the cells' proteins to understand how the drugs function at different doses and time points. Read more...